Paul Eatwell found out he had hepatitis C the way most people do now, through a blood test he was not expecting to raise any flags. He was not ill and he had no reason to think that anything was amiss. It took a routine check to surface a virus that had likely been present for decades, quietly damaging his liver while giving almost no sign of itself. His case is unremarkable in the way that matters most: it describes exactly how the disease usually announces itself in England, which is to say barely at all.

That England is now approaching elimination of hepatitis C, a target the World Health Organization set for 2030 and which the NHS looks set to beat, deserves more scrutiny than the celebratory framing it has received. NHS England figures show more than 100,000 people treated since 2015, an 80% treatment rate against known cases already achieved, and mortality down 36% over the decade. Deaths have not yet fallen far enough to hit the 65% reduction target, and diagnosis rates sit just under the 90% goal, but the trajectory is not in dispute. Antiviral courses lasting eight to twelve weeks now cure more than 95% of cases. For a disease that has no vaccine and was, within living memory, a chronic and often fatal diagnosis, this counts as one of the more significant clinical achievements the NHS has produced this decade.

What makes the story worth examining closely is not the medicine but the method. The programme rests on a long-term commercial drug procurement deal, alongside sustained investment in finding people who did not know they were infected. Since hepatitis C is disproportionately common among drug injectors, inmates, and people with insecure housing, who are populations that traditional healthcare pathways often fail to reach, A&E blood testing, GP registration checks, and free testing at home kits completed the majority of the work. The two factors that predominate in practically every other discussion on NHS performance, better financial settlements and workforce expansion, are not the reason for the NHS's success. It is thriving because of patient, unglamorous infrastructure that targets individuals who the system far too frequently ignores.

There is a harder thread running underneath this, one the coverage has understated. A meaningful proportion of England's hepatitis C burden originates in contaminated blood products administered by the NHS itself between 1970 and 1991, the infected blood scandal that a public inquiry found had been actively covered up by the authorities responsible, with victims knowingly exposed to risk. Around 3,000 people have died as a direct result, and more deaths are still expected. The institution now leading the world toward eliminating this virus is, in some cases, curing harm it caused and then concealed. That is not a footnote. It sits at the centre of what elimination actually means, and it complicates any instinct to treat this purely as good news.

For NHS leadership, the practical lesson is more useful than the moral one. Case-finding combined with a negotiated, guaranteed-volume drug deal is a model that has proved it can shift outcomes for a stigmatised, hard-to-reach population at national scale. Undiagnosed hepatitis B, unmanaged type 2 diabetes in deprived areas, and gaps in tuberculosis detection all share structural similarities with where hepatitis C stood a decade ago. Yet this approach remains the exception in NHS strategy rather than the template. Most public health interventions still assume patients will present themselves to a system that has capacity to see them, an assumption that has grown increasingly shaky under current waiting list pressures.

Elimination, when it is formally reached, will be presented as a triumph of NHS commissioning and clinical delivery, and in narrow terms it will be. But the deeper claim worth making is different. This is what it looks like when an overstretched, frequently criticised health system commits resources over a genuinely long timeframe to people who are hardest to reach and easiest to overlook. The NHS rarely gets credit for patience. This is a case where patience, more than any single reform, did the work.